Ondansetrom Isab (Ondansetron)

Ondansetron, the active ingredient in Ondansetrom Isab, is a 5‑HT3 receptor antagonist presented as an injectable solution for intramuscular and intravenous use. It is employed to prevent and treat nausea and vomiting associated with chemotherapy, radiotherapy and postoperative settings. GNH USA supplies Ondansetrom Isab as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Ondansetron acts on the serotonin pathway to control nausea and vomiting in several clinical contexts. - Chemotherapy‑induced nausea and vomiting: prevents and treats nausea and vomiting associated with cancer chemotherapy. - Radiotherapy‑induced nausea and vomiting: reduces nausea and vomiting triggered by radiation treatment. - Postoperative nausea and vomiting: helps control nausea and vomiting after surgical procedures.

Common Side Effects: - Headache: mild to moderate pain in the head region. - Constipation: reduced bowel movements or hard stools. - Dizziness: sensation of light‑headedness or unsteadiness. - Fatigue: feeling unusually tired or weak. - Diarrhoea: loose, watery stools. - Injection site reactions: pain, erythema or swelling at the site of administration.

Serious or Rare Side Effects: - QT prolongation: abnormal heart rhythm that may lead to arrhythmia. - Severe allergic reactions: anaphylaxis, rash, or swelling of the face and throat. - Serotonin syndrome: potentially life‑threatening condition when combined with other serotonergic agents. - Cardiac arrhythmia: irregular heartbeats beyond QT issues. - Severe hypotension: marked drop in blood pressure requiring medical attention.

Before using Ondansetrom Isab, consider the following precautions: - Assess cardiac risk: monitor ECG in patients with known QT‑interval prolongation. - Avoid concomitant QT‑prolonging drugs: increased risk of arrhythmia when combined with other agents that affect cardiac repolarisation. - Use with caution in hepatic impairment: dose adjustment may be required in patients with liver dysfunction. - Consider renal function: monitor patients with severe renal impairment for accumulation. - Pregnancy and lactation: safety not established; use only if potential benefit justifies the risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Ondansetron may interact with several medicines; awareness of the interaction level is essential. Major Interactions (Avoid): - Other 5‑HT3 antagonists: additive antiemetic effect not recommended. - QT‑prolonging agents (e.g., quinidine, haloperidol): heightened risk of serious cardiac arrhythmias. - Apomorphine: may cause severe hypotension when co‑administered. Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): can increase ondansetron plasma concentrations. - CYP3A4 inducers (e.g., rifampin): may reduce ondansetron effectiveness. - Aprepitant: may raise ondansetron levels, requiring clinical monitoring.